RxDoctor Payments Data

Thomas Cascino, MD

Advanced Heart Failure and Transplant Cardiology · Ann Arbor, MINPI 1679839807

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.8%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Merck at 52.3% of the total.

$39,081in general payments, 2019–2025

Across 74 payments — averaging $528.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$20K
  • Medtronic$9K
  • Actelion Pharmaceuticals US, Inc.$4K
  • Abbott$2K
  • Abiomed$2K
  • Impulse Dynamics (USA) Inc.$1K
  • plus $785 from 4 others
$138,653in research payments, 2019–2025

Across 11 payments — averaging $12,605 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Briohealth Solutions, Inc.$139K

What the payments were for

  • Consulting fees$22,20557%
  • Grants$8,75022%
  • Travel & lodging$5,17413%
  • Food & beverage$2,9528%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,081 in reported general payments places this provider in the 85th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.

See all advanced heart failure and transplant cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$24,479
Medicare patients
110
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil125$3,238,526
AdempasRiociguat35$483,903
OpsumitMacitentan36$453,554
EntrestoSacubitril/Valsartan81$131,925
Ambrisentan29$130,646
JardianceEmpagliflozin90$103,245
EliquisApixaban83$97,887
FarxigaDapagliflozin Propanediol40$55,282
Tadalafil51$33,533
XareltoRivaroxaban14$22,111
Sildenafil Citrate22$5,943
Torsemide66$3,789
Potassium Chloride81$3,604
Eplerenone26$3,069
Metoprolol Succinate104$2,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$3,971$453,55436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.

Other advanced heart failure and transplant cardiology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →